Medication‐related osteonecrosis of the jaw in an older patient with multiple myeloma
- 28 February 2025
- journal article
- case report
- Published by Wiley in Gerodontology
- Vol. 42 (1) , 119-123
Abstract
Objective: This article reports a case of medication‐related osteonecrosis of the jaw (MRONJ) associated with multiple myeloma (MM). Background: Bisphosphonates (BPs) are constantly used as part of the treatment for MM. The main adverse effects of bisphosphonates are renal insufficiency and medication‐related osteonecrosis of the jaw (MRONJ). Materials and Methods: A 67‐year‐old female with a previous diagnosis of MM and undergoing current receiving intravenous injections of pamidronate underwent a tooth extraction and subsequently developed MRONJ. Results: MRONJ was managed with clindamycin, surgical removal of bony sequestrum and curettage. At 3 years of follow‐up, the patient was asymptomatic with no clinical changes and panoramic radiography without evidence of recurrence. Conclusion: Management of patients under antiresorptive drugs who require invasive dental procedures is challenging. Therefore, interprofessional collaboration, especially between the general practitioner and oncologist and/or haematologist, is essential to reach the best clinical approach and reduce the risk of MRONJ.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (420698/2018–3)
This publication has 37 references indexed in Scilit:
- The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk FactorsOral and Maxillofacial Surgery Clinics of North America, 2015
- The multiple oral presentations of multiple myelomaSupportive Care in Cancer, 2013
- Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysisSupportive Care in Cancer, 2012
- Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viabilityBone, 2011
- Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancerBreast Cancer Research and Treatment, 2011
- Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysisBreast Cancer Research and Treatment, 2009
- Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?Bone, 2007
- From Molds and Macrophages to Mevalonate: A Decade of Progress in Understanding the Molecular Mode of Action of BisphosphonatesCalcified Tissue International, 2004
- Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human OsteoblastsBiochemical and Biophysical Research Communications, 2002
- Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow culturesBone, 1996